Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages
The emergence of Omicron lineages and descendent subvariants continues to present a severe threat to the effectiveness of vaccines and therapeutic antibodies. We have previously suggested that an insufficient mucosal immunoglobulin A (IgA) response induced by the mRNA vaccines is associated with a surge in breakthrough infections. Here, we further show that the intramuscular mRNA and/or inactivated vaccines cannot sufficiently boost the mucosal secretory IgA response in uninfected individuals, particularly against the Omicron variant. We thus engineered and characterized recombinant monomeric, dimeric, and secretory IgA1 antibodies derived from four neutralizing IgG monoclonal antibodies (mAbs 01A05, rmAb23, DXP-604, and XG014) targeting the receptor-binding domain of the spike protein. Compared to their parental IgG antibodies, dimeric and secretory IgA1 antibodies showed a higher neutralizing activity against different variants of concern (VOCs), in part due to an increased avidity. Importantly, the dimeric or secretory IgA1 form of the DXP-604 antibody significantly outperformed its parental IgG antibody, and neutralized the Omicron lineages BA.1, BA.2, and BA.4/5 with a 25- to 75-fold increase in potency. In human angiotensin converting enzyme 2 (ACE2) transgenic mice, a single intranasal dose of the dimeric IgA DXP-604 conferred prophylactic and therapeutic protection against Omicron BA.5. Thus, dimeric or secretory IgA delivered by nasal administration may potentially be exploited for the treatment and prevention of Omicron infection, thereby providing an alternative tool for combating immune evasion by the current circulating subvariants and, potentially, future VOCs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:121 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 121(2024), 3 vom: 16. Jan., Seite e2315354120 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marcotte, Harold [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 11.01.2024 Date Revised 24.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1073/pnas.2315354120 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366850628 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366850628 | ||
| 003 | DE-627 | ||
| 005 | 20240124232044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.2315354120 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM366850628 | ||
| 035 | |a (NLM)38194459 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marcotte, Harold |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2024 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The emergence of Omicron lineages and descendent subvariants continues to present a severe threat to the effectiveness of vaccines and therapeutic antibodies. We have previously suggested that an insufficient mucosal immunoglobulin A (IgA) response induced by the mRNA vaccines is associated with a surge in breakthrough infections. Here, we further show that the intramuscular mRNA and/or inactivated vaccines cannot sufficiently boost the mucosal secretory IgA response in uninfected individuals, particularly against the Omicron variant. We thus engineered and characterized recombinant monomeric, dimeric, and secretory IgA1 antibodies derived from four neutralizing IgG monoclonal antibodies (mAbs 01A05, rmAb23, DXP-604, and XG014) targeting the receptor-binding domain of the spike protein. Compared to their parental IgG antibodies, dimeric and secretory IgA1 antibodies showed a higher neutralizing activity against different variants of concern (VOCs), in part due to an increased avidity. Importantly, the dimeric or secretory IgA1 form of the DXP-604 antibody significantly outperformed its parental IgG antibody, and neutralized the Omicron lineages BA.1, BA.2, and BA.4/5 with a 25- to 75-fold increase in potency. In human angiotensin converting enzyme 2 (ACE2) transgenic mice, a single intranasal dose of the dimeric IgA DXP-604 conferred prophylactic and therapeutic protection against Omicron BA.5. Thus, dimeric or secretory IgA delivered by nasal administration may potentially be exploited for the treatment and prevention of Omicron infection, thereby providing an alternative tool for combating immune evasion by the current circulating subvariants and, potentially, future VOCs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IgA | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody engineering | |
| 650 | 4 | |a antibody therapy | |
| 650 | 7 | |a Immunoglobulin A, Secretory |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 700 | 1 | |a Cao, Yunlong |e verfasserin |4 aut | |
| 700 | 1 | |a Zuo, Fanglei |e verfasserin |4 aut | |
| 700 | 1 | |a Simonelli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Sammartino, Josè Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a Pedotti, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Cassaniti, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Hagbom, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Piralla, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jinxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Likun |e verfasserin |4 aut | |
| 700 | 1 | |a Percivalle, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoglio, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Schubert, Maren |e verfasserin |4 aut | |
| 700 | 1 | |a Abolhassani, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Sherina, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Borte, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Nima |e verfasserin |4 aut | |
| 700 | 1 | |a Kumagai-Braesch, Makiko |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Yintong |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Qihong |e verfasserin |4 aut | |
| 700 | 1 | |a He, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Grönwall, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Klareskog, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Calzolai, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalli, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qiao |e verfasserin |4 aut | |
| 700 | 1 | |a Robbiani, Davide F |e verfasserin |4 aut | |
| 700 | 1 | |a Hust, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Zhengli |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Liqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Svensson, Lennart |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Linlin |e verfasserin |4 aut | |
| 700 | 1 | |a Baldanti, Fausto |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Junyu |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Hammarström, Lennart |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xinglou |e verfasserin |4 aut | |
| 700 | 1 | |a Varani, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xiaoliang Sunney |e verfasserin |4 aut | |
| 700 | 1 | |a Pan-Hammarström, Qiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 121(2024), 3 vom: 16. Jan., Seite e2315354120 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:121 |g year:2024 |g number:3 |g day:16 |g month:01 |g pages:e2315354120 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.2315354120 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 121 |j 2024 |e 3 |b 16 |c 01 |h e2315354120 | ||